Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 9/2007

01.09.2007 | Original Paper

Levels of Hepatitis B Virus (HBV) Replication During the Nonreplicative Phase: HBV Quantification by Real-Time PCR in Korea

verfasst von: Hyung Joon Yim, Kwan Soo Byun, Yun Jung Chang, Yeon Seok Suh, Jong Eun Yeon, Chang Hong Lee, Jung Ah Kwon, Wangdon Yoo, Soo-Ok Kim, Sun Pyo Hong

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

The levels of HBV replication in the nonreplicative phase are not clear. We conducted this study to evaluate the levels of viral replication during the nonreplicative phase in chronic HBV-infected Korean patients using real-time PCR. A total of 125 patients were classified into three groups: inactive HBsAg carriers, inactive liver cirrhosis patients, and resolved chronic HBV-infected patients with loss of HBsAg. The real-time PCR detected HBV DNA in 112 cases (89.6%). The mean levels of HBV DNA were 3.84, 4.10, and 3.31 log copies/ml in the three groups, respectively (P <0.01). Ninety-five percent of inactive HBsAg carriers showed levels of HBV DNA lower than 6×104 copies/ml. In conclusion, we showed different levels of HBV DNA exactly in three groups during nonreplicative phases. We suggest that the cutoff level of HBV DNA in inactive HBsAg carriers should be readjusted to a lower level in future studies.
Literatur
1.
Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC (1991) Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology 13:627–631PubMedCrossRef
2.
Papatheodoridis GV, Hadziyannis SJ (2001) Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 8:311–321PubMedCrossRef
3.
4.
Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ (2003) Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 98:2261–2267PubMed
5.
Song BC, Cui XJ, Kim H (2005) Hepatitis B virus genotypes in Korea: An endemic area of hepatitis B virus infection. Intervirology 48:133–137PubMedCrossRef
6.
Lee SH, Han SH, Cho SC, Roh BJ, Sohn JH, Kim DA, Lee DH, Kee CS (2001) Distribution of HBV genotypes in patients with chronic HBV infection in Korea. Korean J Hepatol 7:373–380
7.
Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO (2004) Genetic diversity of hepatitis B virus strains derived worldwide: Genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47:289–309PubMedCrossRef
8.
Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ (2005) Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 97:265–272PubMedCrossRef
9.
Chung HT, Lai CL, Lok AS (1995) Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 22:25–29PubMed
10.
Niesters HG (2001) Quantitation of viral load using real-time amplification techniques. Methods 25:419–429PubMedCrossRef
11.
Nurmi J, Ylikoski A, Soukka T, Karp M, Lovgren T (2000) A new label technology for the detection of specific polymerase chain reaction products in a closed tube. Nucleic Acids Res 28:e28PubMedCrossRef
12.
Ono Y, Onda H, Sasada R, Igarashi K, Sugino Y, Nishioka K (1983) The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res 11:1747–1757PubMedCrossRef
13.
Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A, WHO Collaborative Study Group (2001) An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 80:63–71PubMedCrossRef
14.
Yao JD, Beld MG, Oon LL, Sherlock CH, Germer J, Menting S, Se Thoe SY, Merrick L, Ziermann R, Surtihadi J, Hnatyszyn HJ (2004) Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay. J Clin Microbiol 42:800–806PubMedCrossRef
15.
Pawlotsky JM (2003) Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics. J Hepatol 39(Suppl 1):31–35CrossRef
16.
Aliyu SH, Aliyu MH, Salihu HM, Parmar S, Jalal H, Curran MD (2004) Rapid detection and quantitation of hepatitis B virus DNA by real-time PCR using a new fluorescent (FRET) detection system. J Clin Virol 30:191–195PubMedCrossRef
17.
Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, Valla D, Degott C, Marcellin P (2002) Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 36:543–546PubMedCrossRef
18.
Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL (2004) HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. Hepatology 39:1694–1701PubMedCrossRef
19.
Chen YC, Sheen IS, Chu CM, Liaw YF (2002) Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 123:1084–1089PubMedCrossRef
20.
Fattovich G (2003) Natural history of hepatitis B. J Hepatol 39(Suppl 1):50–58CrossRef
21.
Chu CM, Liaw YF (1997) Natural history of chronic hepatitis B virus infection: An immunopathological study. J Gastroenterol Hepatol 12(Suppl):S218–S222PubMed
22.
Chu CM (2000) Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 15(Suppl):E25–E30PubMedCrossRef
23.
de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, Rumi MG, Donato MF, Ronchi G (1993) The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 118:191–194PubMed
24.
Lindh M, Horal P, Dhillon AP, Norkrans G (2000) Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 7:258–267PubMedCrossRef
25.
Loriot MA, Marcellin P, Walker F, Boyer N, Degott C, Randrianatoavina I, Benhamou JP, Erlinger S (1997) Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol 27:251–258PubMedCrossRef
26.
Gandhi MJ, Yang GG, McMahon B, Vyas G (2000) Hepatitis B virions isolated with antibodies to the pre-S1 domain reveal occult viremia in surface antigen negative/antibody-positive carriers by polymerase chain reaction. Transfusion 40:910–916PubMedCrossRef
27.
Mukaide M, Tanaka Y, Katayose S, Tano H, Murata M, Hikata M, Fujise K, Sakugawa H, Suzuki K, Zaunders J, Nagasawa Y, Toda G, Mizokami M (2003) Development of real-time detection direct test for hepatitis B virus and comparison with two commercial tests using the WHO international standard. J Gastroenterol Hepatol 18:1264–1271PubMedCrossRef
28.
Huo TI, Wu JC, Lee PC, Chau GY, Lui WY, Tsay SH, Ting LT, Chang FY, Lee SD (1998) Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 28:231–236PubMedCrossRef
29.
Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK (2004) Occult hepatitis B virus infection in chronic liver disease: Full-length genome and analysis of mutant surface promoter. Gastroenterology 127:1356–1371PubMedCrossRef
30.
Huy TT, Ushijima H, Win KM, Luengrojanakul P, Shrestha PK, Zhong ZH, Smirnov AV, Taltavull TC, Sata T, Abe K (2003) High prevalence of hepatitis B virus pre-s mutant in countries where it is endemic and its relationship with genotype and chronicity. J Clin Microbiol 41:5449–5455PubMedCrossRef
Metadaten
Titel
Levels of Hepatitis B Virus (HBV) Replication During the Nonreplicative Phase: HBV Quantification by Real-Time PCR in Korea
verfasst von
Hyung Joon Yim
Kwan Soo Byun
Yun Jung Chang
Yeon Seok Suh
Jong Eun Yeon
Chang Hong Lee
Jung Ah Kwon
Wangdon Yoo
Soo-Ok Kim
Sun Pyo Hong
Publikationsdatum
01.09.2007
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 9/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9140-2

Weitere Artikel der Ausgabe 9/2007

Digestive Diseases and Sciences 9/2007 Zur Ausgabe

ORIGINAL ARTICLE

Development of Specific Antibodies to an ARF Protein in Treated Patients with Chronic HCV Infection

Original Article

The Clinicopathological Profile of Indian Patients with Nonalcoholic Fatty Liver Disease (NAFLD) is Different from That in the West

Original Paper

Outcome of ERCP in the Management of Duct-to-Duct Anastomotic Strictures in Orthotopic Liver Transplant

Original Paper

Hypermethylation of SFRP2 as a Potential Marker for Stool-Based Detection of Colorectal Cancer and Precancerous Lesions

Original Paper

Gastric Status and Vitamin B12 Levels in Cardiovascular Patients

Original Article

Risk of Aspiration Pneumonia in Suspected Variceal Hemorrhage: The Value of Prophylactic Endotracheal Intubation Prior to Endoscopy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise